[Immunological Markers in Organ Transplantation]

Area of Science:

• Immunology
• Transplantation Medicine
• Molecular Diagnostics

Background:

• Current organ transplant monitoring relies on surrogate lab markers and invasive biopsies, often diagnosing rejection late.
• Alloreactivity-induced structural damage is difficult to detect non-invasively, delaying timely intervention.
• There is a critical need for early, non-invasive molecular markers to detect rejection and operational tolerance.

Purpose of the Study:

• To review the limitations and potential of novel immunological markers for organ transplantation.
• To highlight the need for early detection of rejection and establishment of operational tolerance.
• To discuss the impact of new biological markers on risk stratification and immunosuppression management.

Main Methods:

• Review of current literature on immunological monitoring in organ transplantation.
• Discussion of high-throughput screening methods for biological signatures (genomics, transcriptomics, proteomics, metabolomics).
• Analysis of advancements in molecular diagnostics for personalized transplantation.

Main Results:

• Despite progress, few new biological markers have been clinically implemented.
• High-throughput screening offers potential for identifying specific signatures of rejection and tolerance.
• Genomic, transcriptomic, proteomic, and metabolomic analyses are paving the way for personalized medicine.

Conclusions:

• Novel non-invasive markers are essential for timely diagnosis and management of transplant rejection and tolerance.
• Personalized transplantation medicine, driven by multi-omics analysis, holds promise for improving long-term graft survival.
• Further research and clinical implementation of new markers are needed to advance transplant care.